aTyr Pharma May Sell Up to $79.99 Million in Shares
aTyr Pharma filed a prospectus supplement for up to $79.99 million of common stock sales through Jefferies, under a shelf registration effective August 18, 2025.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Biotech company aTyr Pharma has filed a prospectus supplement covering the sale of common stock worth up to $79,994,251, according to TradingView, which summarized the filing with the SEC. The shares may be sold from time to time under an Open Market Sale Agreement with Jefferies LLC.
The supplement was made under a Form S-3 shelf registration that was declared effective on August 18, 2025. The company also filed a legal opinion on the legality of shares that may be issued under the sales agreement.
why it matters
For the market this is a routine step: an at-the-market program can dilute existing shareholders if the shares are sold, but the filing alone does not show when or how much will actually be placed. Actual sales will appear in later company reports.
tags
instruments
sources
- aTyr Pharma Files Supplement for Up to $79.99 Million Stock Offering — TradingView, 6 November 2026 at 21:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗